A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial

Anagrelide is an established treatment option for essential thrombocythaemia (ET). A prolonged release formulation was developed with the aim of reducing dosing frequency and improving tolerability, without diminishing efficacy. This multicentre, randomized, double blind, active‐controlled, non‐infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gisslinger, Heinz, Buxhofer‐Ausch, Veronika, Hodisch, Juri, Radinoff, Atanas, Karyagina, Elena, Kyrcz‐Krzemień, Slawomira, Abdulkadyrov, Kudrat, Gerbutavicius, Rolandas, Melikyan, Anait, Burgstaller, Sonja, Hus, Marek, Kłoczko, Janusz, Yablokova, Vera, Tzvetkov, Nikolay, Całbecka, Malgorzata, Shneyder, Tatyana, Warzocha, Krzysztof, Jurgutis, Mindaugas, Kaplanov, Kamil, Jilma, Bernd, Schoergenhofer, Christian, Klade, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594023/
https://www.ncbi.nlm.nih.gov/pubmed/30919941
http://dx.doi.org/10.1111/bjh.15824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594023/
https://www.ncbi.nlm.nih.gov/pubmed/30919941
http://dx.doi.org/10.1111/bjh.15824

Ejemplares similares